Back to today’s briefing

Story perspectives

Pfizer's Flu Vaccine Trials Raise Safety Concerns, Criticized

12/1/2025

41 7 Full Breakdown

Summary

Story summary

Pfizer's mRNA influenza vaccine trials showed adverse events outweighed infections prevented in adults under 65 and failed to show efficacy in those 65 and older.
The elderly cohort recorded 49 deaths in the mRNA group versus 46 in the standard vaccine group.
Investigative journalist Maryanne Demasi criticized the trial design, saying it favored Pfizer's interests and raised questions about safety and effectiveness in the United States.

1 of 1

Story summary

Pfizer's mRNA influenza vaccine trials showed adverse events outweighed infections prevented in adults under 65 and failed to show efficacy in those 65 and older.
The elderly cohort recorded 49 deaths in the mRNA group versus 46 in the standard vaccine group.
Investigative journalist Maryanne Demasi criticized the trial design, saying it favored Pfizer's interests and raised questions about safety and effectiveness in the United States.